Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5218533
Max Phase: Preclinical
Molecular Formula: C19H16N4O2
Molecular Weight: 332.36
Associated Items:
ID: ALA5218533
Max Phase: Preclinical
Molecular Formula: C19H16N4O2
Molecular Weight: 332.36
Associated Items:
Canonical SMILES: COc1ccc(-c2cnc3c(c2)nnn3-c2ccccc2)cc1OC
Standard InChI: InChI=1S/C19H16N4O2/c1-24-17-9-8-13(11-18(17)25-2)14-10-16-19(20-12-14)23(22-21-16)15-6-4-3-5-7-15/h3-12H,1-2H3
Standard InChI Key: QFWTYDYTUMGDGW-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 332.36 | Molecular Weight (Monoisotopic): 332.1273 | AlogP: 3.50 | #Rotatable Bonds: 4 |
Polar Surface Area: 62.06 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 3.56 | CX LogD: 3.56 |
Aromatic Rings: 4 | Heavy Atoms: 25 | QED Weighted: 0.57 | Np Likeness Score: -1.31 |
1. Callis TB, Garrett TR, Montgomery AP, Danon JJ, Kassiou M.. (2022) Recent Scaffold Hopping Applications in Central Nervous System Drug Discovery., 65 (20.0): [PMID:36206553] [10.1021/acs.jmedchem.2c00969] |
Source(1):